Biotechnology company Alligator Bioscience (Nasdaq Stockholm:ATORX) announced Tuesday that it has entered into a license agreement for an antibody from ALLIGATOR-GOLD for up to three bispecific molecules with Chinese biotechnology company Biotheus Inc.
Based in Zhuhai, Guangdong, China, Biotheus has received the rights in Greater China, including Republic of China, Hongkong, Taiwan and Macau, to an antibody from Alligator Bioscience' ALLIGATOR-GOLD for the creation of up to three bispecific molecules, with focus on immuno-oncology and metabolic disease area.
The agreement includes an option to Biotheus Inc for expanding the antibody license to global rights.
Under the license agreement, Alligator receives USD0.5m upon signing and USD0.5m after six months of scientific-technical evaluation.
In conjunction with the agreement Alligator is eligible to receive up to a total of approximately USD142m in upfront and development milestones payments, global option fees as well as royalties on future sales and share of sub-license revenue.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval